research. Thanks, Chad. Starting with life sciences first
We of business important as are products and their repertoire of additional In profiling, by the across expand community for Since is a XXXX, sequencing partners in usage of monitoring research companies have been make MRD for XX and date. services. for partners using clonoSEQ biopharma our continuing beginning particular, immune selected clinical the our to immuno total our trials. to our progress increasingly an assays XXX immunoSEQ biopharma
kit that will end sample we immunoSEQ including work year, the by this upgraded with stored any are quantitatively mentioned, Chad As of RUO samples. type, launching tissue an for
for As distribution. the states, team growing our we sequencing sales immuno of use expands marketing seeking disease partners and and across global are
standardized industry important it for the a a inclusion to the MRD have blood trials. is continues primary MRD highly in endpoint As for accurate as surrogate potential assess trials option increasingly of testing in cancers, to and or clinical registrational
and plays fees sequencing Of global milestones. in a of the agreement, for our annual the drug testing across note, of type assess in of with in use in will announced clonoSEQ exemplifies development programs portfolio. MRD growing to agreement QX efficacy Under payments we This MRD multiple we receive regulatory clinical this trials. assay to role demonstrating the addition in terms potential development partnership Amgen their drug
coverage. to HEMOCs just XXX are test volumes compared Progress X growing increased following to with next Starting small months clinical clonoSEQ institutions. force. than Clinical with clonoSEQ, during date tests test our XXXX. X,XXX in to of third used CMS achieved over the a the been third quarter XX% is expectations XXX by volumes clinical Turning by to currently more diagnostics. in field line XX-person has quarter
support coverage broader months. in adoption aim field the market mentioned, an triggered expedite have integration the achieve next We in the As U.S., accelerated to the clonoSEQ more to commercial across to Chad team activation double by the growing need and processes. account we XX for XXXX and resources January demand to than workflow over our expansion to response
marketing so knowing also of status. patients that are of MRD are efforts our ramping We their the aware importance up more
MRD community by clinical clonoSEQ, the for we for obtaining importance before protocols burden and to biopharma confirm and therapy, after disease and-or confirm cases each to evidence. to expand the through baseline partner patient. sponsored world real continually us data This sample transplant, about using of Today, remission longitudinal methods of guide patient. test traditional are over generating maintenance lifetime complete determine will We are use educating regular therapy. a response monitoring a registry the curate clinicians investigator trials, patient are To enable to already perform the every the
ALL, clonoSEQ submission to expansion we regards to With management, label first for patients to with monitor track CLL end used on from the to for patients to underway of to also in bone our is utility are to and with FDA blood label be by to extend blood myeloma the samples. Work multiple lifecycle XXXX our samples. blood also NHL, from from and expand marrow current with
into costly Moving preferred by system. patients the and be less will to significantly highly blood healthcare
end, for and with We are test access to diagnostic a our exploring To greater local Illumina that diagnostic may utilization of allow labs. announced of development extensions for in-vitro we products. product enable line kits that partnership the
will that are MRD ensuring that will monitor it the manage their is standardized committed confident tools to early their have clonoSEQ days, are and to available that use the tool We patients. disease, we patients to access still clinicians while to become best monitoring
the confirmation product to setting out retrospective testing. immunoSEQ and one signature, product, product pipeline disease clinical by This the different a serological will two DX. TCR standard signal been based plus validation diagnose we To learning these is on compared machine antigens, of will response calling this of confirm in of clinical intended continuously have leveraging immune cohorts. XXX acute In are to This improve medicine signature. has by which diagnostic at patient in least studies, our disease which line into XXXX. and to clinical we Microsoft's signal take our identify to launch XXXX to now both specific disease Each platform from is care, the two-tiered disease Turning we we XXXX, to achieved set a in which T-cell expertise. TCR end independent
Our behind false of specific over standard are we our the sensitivity more false additional receptors by intend Lyme represented clinical that disease, confirmed. We run detecting States a million and disease patient run. negative T-cell are tests data over and test collect X.X and XXX,XXX rates year registrational that science identifying the in continually line cases reduction over disease. as year our in in compared line we cohorts In validation with Lyme the based with to This whose in been receptors accuracy shows newly believe can the improve disease have each immunoSEQ approximately significantly diagnosed next of We patients in both identified detection specific acute clinically care. There Lyme patients increase patient DX. diagnostic this blood each the study. United on expansion the TCRs positive cohort, to line signal the of of of de-risks
We volunteers study for other future. such states celiac research we October, studies may also continue disease have in celiac several to states in that progress in to believe and we disease. we discussed In disease disease, sponsor such a the as opened near have other X,XXX who they plan additional
We are the our to commercial to our product DX, with for now define and to necessary immunoSEQ FDA expanding market. bring validation this working protocols team
Turning drug discovery. now to
our TCR with progressing screening cellular oncology to to process and use is develop partnership Genentech well. in therapies Our discovery
goal therapy contributed of to prioritized significant cellular generation cell we the shared is IND version the for filing TCRs against previously the XXXX. the product data our many In TCRs of using of Genentech QX, against in antigens. development As therapy discussed, focusing packages antigen first packages, these From resources we products are TCRs of on off the shared prioritizing on shelf data with development targets.
a product, make with in the specific therapy each the also we identify to where TCRs of patient's are on We plan continuing Genentech to are that progress real tumor. development time to cellular personalized
In sum, advance execute pipeline. traction our on and our we are beginning against clinical commercial we products all as fronts to gain
margin, to high our specific market. leverage patient are our in immune to We confident immune-driven platform ability medicine bring products to
to more for C. our that, the now With Chad? call on I over financials. Chad will turn details
